#USA #Stockholm #Sobi #Gout Treatment #pozdeutinurad

Positive Phase 3 Trial Results for Pozdeutinurad in Gout

Sobi® (STO: SOBI) recently revealed encouraging topline results from its pivotal Phase 3 REDUCE 2 study. This clinical trial focuses on pozdeutinurad (AR882), a next-generation oral selective URAT1 inhibitor designed for adults suffering from gout, particularly those with uncontrolled or inadequately controlled conditions.

Study Overview

The REDUCE 2 study, registered under NCT06439602, was crucial in evaluating pozdeutinurad's efficacy. It involved 811 participants who were randomized into three groups, receiving either 50mg or 75mg of pozdeutinurad, or a placebo over a six-month period. The primary endpoint was the percentage of patients reaching a serum uric acid (sUA) level below 6 mg/dL. Results showed that both doses of pozdeutinurad significantly surpassed the placebo in achieving this benchmark, leading to impressive percentages of 69.2% and 56.6%, respectively, versus just 8.1% for the placebo cohort.

Efficacy and Safety Profile

The safety profile of pozdeutinurad remained consistent with findings from previous research, adding to the treatment’s credibility. Dr. Lydia Abad-Franch, Sobi’s Head of Research & Development and Chief Medical Officer, expressed optimism about the trial outcomes and their implications for patients whose gout remains inadequately managed. She emphasized that these results point to pozdeutinurad's potential to fill a significant therapeutic gap in the management of gout, particularly for those unable to adequately respond to existing treatments.

Potent Treatment for Uncontrolled Gout

Despite the availability of several urate-lowering therapies, many patients find themselves inadequately treated, leading to uncontrolled gout. This can result in severe immediate and long-term complications, including recurrent flares, joint damage, and increased risks of comorbidities like kidney diseases and cardiovascular complications. Pozdeutinurad's promising results highlight its importance as a much-needed treatment option for those still struggling to achieve target uric acid levels, enhancing their quality of life.

Focus on Future Research

Sobi’s ongoing commitment to research and development is underscored by its acquisition of Arthrosi, Inc., a biotechnology company dedicated to gout therapies, which expanded its drug portfolio to include pozdeutinurad in February 2026. The REDUCE 2 study is one among the two global Phase 3 investigations Sobi has initiated, with the other being REDUCE 1, which also aims to assess the drug's efficacy in gout patients. Both studies employ rigorous randomized, double-blind, placebo-controlled methodologies, further solidifying the agreement of their scientific rigor.

Importance of Addressing Gout Challenges

Gout remains the most prevalent form of inflammatory arthritis, marked by painful flares due to elevated uric acid levels. Prolonged accumulation of uric acid without effective management can lead to serious health consequences. Hence, there is a significant unmet need for accessible and effective gout treatments, making the trial results for pozdeutinurad especially salient.

Pozdeutinurad (AR882) emerges as a powerful potential solution for patients burdened by this condition. The Phase 2 studies have already demonstrated substantial effectiveness in lowering serum uric acid levels, supporting its projected use in larger populations battling gout.

Final Thoughts

As we await more detailed results to be presented at a scientific congress later this year, the findings from REDUCE 2 give patients and healthcare professionals alike reason for optimism. Pozdeutinurad stands at the frontier of igniting innovative treatment pathways for those afflicted with gout, propelling Sobi forward in advancing health for individuals suffering from chronic diseases.